Related references
Note: Only part of the references are listed.Time spent with residual viraemia after virological suppression below 50 HIV-RNA copies/mL according to type of first-line antiretroviral regimen
Nicola Gianotti et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2018)
Impact of baseline plasma HIV-1 RNA and time to virological suppression on virological rebound according to first-line antiretroviral regimen
Francois Raffi et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2017)
Determinants of residual viraemia during combination HIV treatment: Impacts of baseline HIV RNA levels and treatment choice
E. McKinnon et al.
HIV MEDICINE (2016)
Residual immune activation in combined antiretroviral therapy-treated patients with maximally suppressed viremia
Amelie Guihot et al.
AIDS (2016)
Persistent HIV-1 replication during antiretroviral therapy
Javier Martinez-Picado et al.
CURRENT OPINION IN HIV AND AIDS (2016)
Integrase inhibitor versus protease inhibitor based regimen for HIV-1 infected women (WAVES): a randomised, controlled, double-blind, phase 3 study
Kathleen Squires et al.
LANCET HIV (2016)
HIV-1 Very Low Level Viremia Is Associated with Virological Failure in Highly Active Antiretroviral Treatment-Treated Patients
Andrea Calcagno et al.
AIDS RESEARCH AND HUMAN RETROVIRUSES (2015)
Factors Associated with Low-Level Viraemia and Virological Failure: Results from the Austrian HIV Cohort Study
Gisela Leierer et al.
PLOS ONE (2015)
Immunologic and Virologic Progression in HIV Controllers: The Role of Viral Blips and Immune Activation in the ANRS CO21 CODEX Study
Nicolas Noel et al.
PLOS ONE (2015)
Factors Associated With CD8+ T-Cell Activation in HIV-1-Infected Patients on Long-term Antiretroviral Therapy
Lu Zheng et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2014)
Virological outcome at week 48 of three recommended first-line regimens using ultrasensitive viral load and plasma drug assay
Charlotte Charpentier et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2014)
The Role of Baseline HIV-1 RNA, Drug Resistance, and Regimen Type as Determinants of Response to First-Line Antiretroviral Therapy
Antonio Di Biagio et al.
JOURNAL OF MEDICAL VIROLOGY (2014)
Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study
Bonaventura Clotet et al.
LANCET (2014)
Association of Residual Plasma Viremia and Intima-Media Thickness in Antiretroviral-Treated Patients with Controlled Human Immunodeficiency Virus Infection
Anders Boyd et al.
PLOS ONE (2014)
Increasing HIV-1 Non-B Subtype Primary Infections in Patients in France and Effect of HIV Subtypes on Virological and Immunological Responses to Combined Antiretroviral Therapy
Marie-Laure Chaix et al.
CLINICAL INFECTIOUS DISEASES (2013)
Virological rebound in human immunodeficiency virus-infected patients with or without residual viraemia: results from an extended follow-up
N. Gianotti et al.
CLINICAL MICROBIOLOGY AND INFECTION (2013)
Dolutegravir plus Abacavir-Lamivudine for the Treatment of HIV-1 Infection
Sharon L. Walmsley et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Circulating interleukin-6 levels correlate with residual HIV viraemia and markers of immune dysfunction in treatment-controlled HIV-infected patients
Jean-Philippe Bastard et al.
ANTIVIRAL THERAPY (2012)
HIV-1 low-level viraemia assessed with 3 commercial real-time PCR assays show high variability
Jean Ruelle et al.
BMC INFECTIOUS DISEASES (2012)
Plasma HIV-1 RNA Detection Below 50 Copies/mL and Risk of Virologic Rebound in Patients Receiving Highly Active Antiretroviral Therapy
Tomas Doyle et al.
CLINICAL INFECTIOUS DISEASES (2012)
Ultrasensitive Assessment of Residual Low-Level HIV Viremia in HAART-Treated Patients and Risk of Virological Failure
Franco Maggiolo et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2012)
Nevirapine use, prolonged antiretroviral therapy and high CD4 nadir values are strongly correlated with undetectable HIV-DNA and -RNA levels and CD4 cell gain
Loredana Sarmati et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2012)
Modest Nonadherence to Antiretroviral Therapy Promotes Residual HIV-1 Replication in the Absence of Virological Rebound in Plasma
Alexander O. Pasternak et al.
JOURNAL OF INFECTIOUS DISEASES (2012)
Magnitude of Virologic Blips Is Associated With a Higher Risk for Virologic Rebound in HIV-Infected Individuals: A Recurrent Events Analysis
J. Troy Grennan et al.
JOURNAL OF INFECTIOUS DISEASES (2012)
Higher efficacy of nevirapine than efavirenz to achieve HIV-1 plasma viral load below 1 copy/ml
Stephanie Haim-Boukobza et al.
AIDS (2011)
CD4 Dynamics over a 15 Year-Period among HIV Controllers Enrolled in the ANRS French Observatory
Faroudy Boufassa et al.
PLOS ONE (2011)
Persistent Low-Level Viremia in HIV-1 Elite Controllers and Relationship to Immunologic Parameters
Florencia Pereyra et al.
JOURNAL OF INFECTIOUS DISEASES (2009)
Ultrasensitive Assessment of Residual HIV Viraemia in HAART-Treated Patients With Persistently Undetectable Plasma HIV-RNA: A Cross-Sectional Evaluation
Stefano Bonora et al.
JOURNAL OF MEDICAL VIROLOGY (2009)
Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial
Jeffrey L. Lennox et al.
LANCET (2009)
HIV-1 Residual Viremia Correlates with Persistent T-Cell Activation in Poor Immunological Responders to Combination Antiretroviral Therapy
Maud Mavigner et al.
PLOS ONE (2009)
Viral reservoirs, residual viremia, and the potential of highly active antiretroviral therapy to eradicate HIV infection
Lin Shen et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2008)
Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy
Sarah Palmer et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Does patient sex affect human immunodeficiency virus levels?
M Gandhi et al.
CLINICAL INFECTIOUS DISEASES (2002)
Share Paper
